|
1
|
Herbst RS, Fukuoka M and Baselga J:
Gefitinib - a novel targeted approach to treating cancer. Nat Rev
Cancer. 4:956–965. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wheeler DL, Dunn EF and Harari PM:
Understanding resistance to EGFR inhibitors - impact on future
treatment strategies. Nat Rev Clin Oncol. 7:493–507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich
H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR
mutants and inhibitor complexes: Mechanism of activation and
insights into differential inhibitor sensitivity. Cancer Cell.
11:217–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Agus DB, Akita RW, Fox WD, Lewis GD,
Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K,
et al: Targeting ligand-activated ErbB2 signaling inhibits breast
and prostate tumor growth. Cancer Cell. 2:127–137. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baselga J, Rischin D, Ranson M, Calvert H,
Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, et al:
Phase I safety, pharmacokinetic, and pharmacodynamic trial of
ZD1839, a selective oral epidermal growth factor receptor tyrosine
kinase inhibitor, in patients with five selected solid tumor types.
J Clin Oncol. 20:4292–4302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scagliotti GV, Selvaggi G, Novello S and
Hirsch FR: The biology of epidermal growth factor receptor in lung
cancer. Clin Cancer Res. 10:4227s–4232s. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maurizi M, Almadori G, Ferrandina G,
Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti
G, Scambia G and Mancuso S: Prognostic significance of epidermal
growth factor receptor in laryngeal squamous cell carcinoma. Br J
Cancer. 74:1253–1257. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tateishi M, Ishida T, Kohdono S, Hamatake
M, Fukuyama Y and Sugimachi K: Prognostic influence of the
co-expression of epidermal growth factor receptor and c-erbB-2
protein in human lung adenocarcinoma. Surg Oncol. 3:109–113. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robertson SC, Tynan J and Donoghue DJ: RTK
mutations and human syndromes: When good receptors turn bad. Trends
Genet. 16:3682000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al Spanish Lung Cancer Group: Screening for epidermal growth
factor receptor mutations in lung cancer. N Engl J Med.
361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robinson KW and Sandler AB: EGFR tyrosine
kinase inhibitors: Difference in efficacy and resistance. Curr
Oncol Rep. 15:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong D, Ru Y, Wang Q, Zhang J, Zhang J,
Wei J, Wu J, Yao L and Li X and Li X: Chimeric ubiquitin ligases
inhibit non-small cell lung cancer via negative modulation of EGFR
signaling. Cancer Lett. 359:57–64. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Pan J, Dong Y, Tweardy DJ, Dong
Y, Garibotto G and Mitch WE: Stat3 activation links a C/EBPδ to
myostatin pathway to stimulate loss of muscle mass. Cell Metab.
18:368–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tierney MT, Aydogdu T, Sala D, Malecova B,
Gatto S, Puri PL, Latella L and Sacco A: STAT3 signaling controls
satellite cell expansion and skeletal muscle repair. Nat Med.
20:1182–1186. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur
C, Sun J, Li L, Kowluru A and Chen F: Gefitinib resistance resulted
from STAT3-mediated Akt activation in lung cancer cells.
Oncotarget. 4:2430–2438. 2013.PubMed/NCBI
|
|
17
|
Zhao D, Zhu MX, Wang Y, Shen Q and Li JX:
Pd(0)-catalyzed benzylic arylation-oxidation of
4-methylquinazolines via sp3 C-H activation under air
conditions. Org Biomol Chem. 11:6246–6249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao D, Wang T, Shen Q and Li JX:
n-Bu4NI-catalyzed selective dual amination of
sp3 C-H bonds: Oxidative domino synthesis of
imidazo[1,5-c]quinazolines on a gram-scale. Chem Commun.
50:4302–4304. 2014. View Article : Google Scholar
|
|
19
|
Zhang L, Gao Z, Peng C, Bin ZY, Zhao D, Wu
J, Xu Q and Li JX: Ultrasound-promoted synthesis and
immunosuppressive activity of novel quinazoline derivatives. Mol
Divers. 16:579–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao D, Shen Q, Zhou YR and Li JX:
KOtBu-mediated stereose-lective addition of quinazolines to alkynes
under mild conditions. Org Biomol Chem. 11:5908–5912. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang D and Gao F: Quinazoline derivatives:
Synthesis and bioactivities. Chem Cent J. 7:952013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harada D, Takigawa N and Kiura K: The role
of STAT3 in non-small cell lung cancer. Cancers. 6:708–722. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pathak AK, Bhutani M, Nair AS, Ahn KS,
Chakraborty A, Kadara H, Guha S, Sethi G and Aggarwal BB: Ursolic
acid inhibits STAT3 activation pathway leading to suppression of
proliferation and chemosensitization of human multiple myeloma
cells. Mol Cancer Res. 5:943–955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bharti AC, Donato N and Aggarwal BB:
Curcumin (diferuloylmethane) inhibits constitutive and
IL-6-inducible STAT3 phosphorylation in human multiple myeloma
cells. J Immunol. 171:3863–3871. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baskin R, Majumder A and Sayeski PP: The
recent medicinal chemistry development of Jak2 tyrosine kinase
small molecule inhibitors. Curr Med Chem. 17:4551–4558. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
28
|
Yang SH, Khadka DB, Cho SH, Ju HK, Lee KY,
Han HJ, Lee KT and Cho WJ: Virtual screening and synthesis of
quinazolines as novel JAK2 inhibitors. Bioorg Med Chem. 19:968–977.
2011. View Article : Google Scholar
|
|
29
|
LaPorte MG, da Paz Lima DJ, Zhang F, Sen
M, Grandis JR, Camarco D, Hua Y, Johnston PA, Lazo JS, Resnick LO,
et al: 2-Guanidinoquinazolines as new inhibitors of the STAT3
pathway. Bioorg Med Chem Lett. 24:5081–5085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
